Cell line · CVCL_0392
Papers44
1 to 20 of 44
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The regulation of protein phosphatase 4 by FBXO42 is required for cancer cell survival. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation. | Cells | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal. | Biomolecules | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The protease-activated receptors are expressed in glioblastoma and differentially modulate adherent versus stem-like growth of LN-18 GBM cells. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR). | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion. | Cell Death Dis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Annexin A2 Stabilizes Oncogenic JAG1 Intracellular Domain by Inhibiting Proteasomal Degradation in Glioblastoma Cells. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma. | Front Cell Dev Biol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. | Proc Natl Acad Sci U S A | 2021 | Its Methods give the RRID and name the line | PubMed | |
| High-resolution, ultrasensitive and quantitative DNA double-strand break labeling in eukaryotic cells using i-BLESS. | Nat Protoc | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0392/papers